Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
about
Insights into APC/C: from cellular function to diseases and therapeuticsCell Division Cycle 6 Promotes Mitotic Slippage and Contributes to Drug Resistance in Paclitaxel-Treated Cancer CellsProtein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN)Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress.Stressing mitosis to death.Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all.Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer.Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma.Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer.Peptide inhibitors of the anaphase promoting-complex that cause sensitivity to microtubule poison.Magnetic nanoparticle hyperthermia potentiates paclitaxel activity in sensitive and resistant breast cancer cellsInhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule-targeting agents by blocking cytokinesis
P2860
Q26740196-DCCB51A5-BB27-42BA-A804-6CE6B32D0913Q28553956-D089CB01-2EBC-44BF-9AE7-8E2537237A88Q36187549-37780919-E333-4EA3-A7C1-36B15B7250FBQ36188433-92347DE2-87EC-4B3B-B43F-9C7C993A81DFQ37295389-9A5104F5-B192-45B4-9522-DF954A540A81Q38219980-5A989221-504D-4F49-9545-C2F5E582DE5CQ38561332-FCE4BD77-D2DA-4AE5-8879-AEF81D65607DQ41866064-E462B89E-BF13-488F-AB1F-13000B7B6983Q48522177-2C1BF9ED-00B9-45C4-A55C-76EC11783731Q53684279-1270A176-7913-4568-8912-DBE74A8192EEQ55047891-EA5EB567-394A-4A23-AC33-DEA51D009CF2Q55099755-6EA05117-EE1B-40EC-A7C2-FEB3801F07E1Q57167802-D5FC45A5-0757-46F8-A83F-6F1C8376D347Q58783840-C3341AEE-7CDF-453D-B918-26057EA44B62
P2860
Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@en
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@nl
type
label
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@en
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@nl
prefLabel
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@en
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@nl
P2093
P2860
P356
P1433
P1476
Targeting mitotic exit with hy ...... increase paclitaxel efficacy.
@en
P2093
Alexander M Ishov
Dhruv Bellapu
Serena Giovinazzi
Viacheslav M Morozov
P2860
P304
P356
10.4161/CC.25591
P577
2013-07-09T00:00:00Z